OBJECTIVES: The aim of this study is to evaluate the pharmacoeconomic evaluation of fixed doses combination insulin glargine U 100/mL+lixisenatide versus insulin glargine U 100/mL+exenatide treatment in type 2 diabetes mellitus (T2DM) in Turkiye.

METHODS: Cost minimization analysis was used to model T2DM treatment in Turkiye. The analyzes of the study were conducted from the perspective of the payer institution and for one year. In the study, the number and rate of annual medicines cost, outpatient visits of T2DM patients, imaging and laboratory tests, hospitalizations and interventions were obtained from expert opinion, epidemiological studies, and literature studies. The costs of health uses have been calculated over the Social Security Institution Health Implementation Communiqué.

RESULTS: As a result of the calculations, the average cost of the physician visit (1.296,25 TL vs 1.317,74 TL), the cost of laboratory and imaging tests (877,73 TL), and the cost of hospitalization and interventions (1.480,01 TL) were found to be almost the same for the two treatments evaluated in Turkiye. Medicines costs were found to be 16.773,71 TL for fixed dose combination of insulin glargine U 100/mL + lixisenatide and 20.806,77 TL for insulin glargine + exenatide. According to these results, the total cost of fixed dose combination of insulin glargine U 100/mL + lixisenatide was 20.427,69 TL and the total cost of insulin glargine+exenatide treatment was 24.482,24 TL. Within all these results, a cost difference of -4.054,55 TL emerges between fixed dose combination of insulin glargine U 100/mL+lixisenatide and insulin glargine+ exenatide.

CONCLUSIONS: As a result of cost minimization analysis, fixed dose combination of insulin glargine U 100/mL + lixisenatide treatment meets the requirements for cost minimization when compared to insulin glargine and exenatide therapies in patients with T2DM. The use of fixed dose combination of insulin glargine U 100/mL+lixisenatide in the treatment of T2DM patients would provide cost-saving.